Admiral
“Each year, the
This year’s conference will touch on a number of important topics, including the impact of SCD on patients and caregivers and exploring the caregiver experience throughout the continuum of care, as well a discussion of the national SCD legislative agenda.
“We are excited for the opportunity to bring together leading physicians, warriors, advocates, and policymakers to discuss the next frontiers in SCD and how we can continue to drive meaningful change in the community,” said
In addition to
- The Honorable
Chris Van Hollen ,U.S. Senator,Maryland Lewis Hsu , M.D., Ph.D., Chief Medical Officer, Director of the Sickle Cell Center and Professor of Pediatrics; Pediatric Hematologist,University of Illinois at Chicago Alan Anderson , M.D., Assistant Professor ofClinical Pediatrics ,University of South Carolina School of Medicine ,Greenville, South Carolina ; Medical Director, Comprehensive Sickle Cell Disease Program,Prisma Health Kofi Anie , MBE, Ph.D., AFBPsS, Psychology Service Lead,London North West University Healthcare NHS Trust Richard Drachtman , M.D., Clinical Section Chief, Pediatric Hematology/Oncology Division; Medical Director, Pediatric Hematology/Oncology Clinical Program; Professor ofPediatrics Rutgers Cancer Institute of New Jersey ,Rutgers Robert Wood Johnson Medical School Marsha Treadwell , Ph.D., Professor of Pediatrics,Division of Hematology , and Jordan Fund Endowed Chair at theUniversity of California San Francisco (UCSF); Co-Chair of the Diversity, Equity and Inclusion Council for the UCSF Benioff Children’s HospitalsAyana L. Johnson , SCDAA National Teen AmbassadorHermionne Johnson , R.N., M.S.N., SCD CaregiverRonisha Edwards-Elliot ,SCD Patient Advocate Rebecca Robbins , SCD CaregiverJennifer George , B.A. &Stephanie George ,B.Sc .,M.Sc ., SCD Patient Advocates & CaregiversBiree Andemariam , M.D., Professor of Medicine, American Red Cross Endowed Chair in Transfusion Medicine,Division of Hematology/Oncology ; Director,New England Sickle Cell Institute ,University of Connecticut Health ; Vice Chair of the Board, SCDAAChancellor Donald , M.D., Chair,American Society of Hematology (ASH) Committee on Practice ; Assistant Professor,Tulane University School of Medicine
Multiple companies that have and are developing treatments for patients with SCD will present at the conference, including Agios Pharmaceuticals,
For more information about the conference or to register to attend, visit http://scdconference.com/. Follow the conversation on Twitter using the hashtag #SCDTC.
About Sickle Cell Disease
It is estimated that more than 100,000 people in the United States,1 52,000 people in Europe,2 up to 100,000 people in Brazil,3 and millions of people throughout the world have sickle cell disease (SCD).1 SCD occurs particularly among those whose ancestors are from sub-Saharan Africa, though it also occurs in people of Hispanic, South Asian, Southern European and Middle Eastern ancestry.1 SCD is a lifelong inherited blood disorder that impacts hemoglobin, a protein carried by red blood cells that delivers oxygen to tissues and organs throughout the body.4 Due to a genetic mutation, individuals with SCD form abnormal hemoglobin known as sickle hemoglobin. When sickle hemoglobin becomes deoxygenated, it polymerizes to form rods, which deforms the red blood cells into sickled – crescent-shaped, rigid – cells.4-6 The recurrent sickling process causes destruction of the red blood cells, hemolysis and anemia (low hemoglobin due to red blood cell destruction), which drives vascular inflammation contributing to blockages in capillaries and small blood vessels (vaso-occlusion) that impede the flow of blood and oxygen delivery throughout the body. Episodes of painful vascular occlusions are commonly referred to as vaso-occlusive crises (VOCs). The diminished oxygen delivery to tissues and organs can lead to life-threatening complications, including stroke and irreversible organ damage.5-9 Complications of SCD begin in early childhood and can include neurocognitive impairment, acute chest syndrome, and silent and overt stroke, among other serious issues.10 Early intervention and treatment of SCD have shown potential to modify the course of this disease, reduce symptoms and events, prevent long-term organ damage, and extend life expectancy.5
About Global Blood Therapeutics
About SCDAA
SCDAA’s mission is: To advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure. Visit http://www.sicklecelldisease.org/.
References
Centers for Disease Control and Prevention . Sickle Cell Disease Data and Statistics (SCD). https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed June 7, 2022.European Medicines Agency . https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125. Accessed June 12, 2022.- Ministério da Saúde (Brasil), Protocolo Clínico e Diretrizes Terapêuticas da Doença Falciforme, Feb. 19, 2018
- National Heart, Lung, and Blood Institute. Sickle Cell Disease. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease. Accessed February 23, 2022.
- Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.
- Rees DC, et al.
Lancet . 2010;376(9757):2018-2031. - Kato GJ, et al. J Clin Invest. 2017;127(3):750-760.
- Caboot JB, et al. Paediatr Respir Rev. 2014;15(1):17-23.
- Nader E, et al. Front Immunol. 2020 Mar 13;11:454.
- Kanter J, et al. Blood Rev. 2013 Nov;27(6):279-87.
Contact:
Steven Immergut (media)
+1 650-410-3258
simmergut@gbt.com
Courtney Roberts (investors)
+1 650-351-7881
croberts@gbt.com
SCDAA Contact Information:
eday@sicklecelldisease.org
kjacobs@sicklecelldisease.org
Source:
2022 GlobeNewswire, Inc., source